Advanced Medical Optics, Inc. Receives FDA Approval for Advanced CustomVue(TM) Monovision Procedure for the Treatment of Presbyopic Myopes

SANTA ANA, Calif.--(BUSINESS WIRE)--Advanced Medical Optics, Inc. (AMO) [NYSE:EYE], a global leader in ophthalmic surgical devices and eye care products, today announced the U.S. Food and Drug Administration (FDA) has approved the Advanced CustomVue™ Monovision procedure, the first wavefront-guided laser vision correction procedure for the visual correction of myopic (nearsighted) presbyopic patients, with and without astigmatism.

MORE ON THIS TOPIC